The number of prescriptions for non-steroidal anti-inflammatory drugs (NSAIDS), which are contraindicated for hypertension, asthma patients, and pregnant women, was continuously increasing.
Celecoxib took up the most prescription ingredients, and Celebrex recorded the most prescriptions. In particular, Daewon's Pelubi drew attention as it was making significant progress by expanding its indications.
NSAIDS prescription volume is increasing every year, increasing the proportion of Celecoxib
As a result of the Medical Times' investigation of the NSAIDS prescription status through IQVIA, a drug market research organization, it was analyzed that the amount of prescriptions and sales have been steadily increasing in recent years.

Actually, the sales of NSAIDS in Korea exceeded ₩500 billion in 2017, and since then, it has recorded a double-digit increase every year to ₩545 billion in 2018 and ₩560 billion in 2019. As sales from the first half of this year (January to June) have already exceeded ₩265 billion, the sales amount of NSAIDS is expected to exceed ₩500 billion this year.

Despite the prolonged COVID-19 pandemic, most drug prescriptions and sales have plummeted to less than 30%, but sales of NSAIDS are significant. As the indications are increased through safety, the prescription of Celecoxib, which is a mechanism of selective cox 2 inhibition, is increasing significantly.

Since it recorded ₩59.2 billion in sales in 2017, it has been dominating the market by significantly increasing to ₩68.3 billion in 2018 and ₩75.1 billion in 2019. Although Loxoprofen recorded a sales amount similar to that of Celecoxib at ₩52.1 billionin 2017, it is a significant step forward compared to slowing growth to ₩56.5 billion in 2018 and ₩59.1 billion in 2019.

Aceclofenac sold ₩51.3 billion last year, ranking in third place, and Aspirin (ACETYLSALICYLIC ACID sold ₩43.8 billion.

Celebrex sales are large and Pelubi's growth is outstanding
By product, Celebrex, which is also highly trusted for its safety, was still dominating the market.

Since #Celebrex recorded sales of ₩32.6 billion in 2017, it has increased to ₩36.4 billion in 2018 and surpassed ₩40 billion in 2019. Since it has already sold ₩19 billion in the first half of this year alone, and it will exceed ₩40 billion this year. Daewon's Pelubi, followed closely by Celebrex, showed a terrifying growth recently.

Pelubi's sales in 2017 were only ₩11 billion, but it nearly doubled to ₩20.8 billion in 2018, a year later, and sold ₩22 billion in 2019, finally overtaking aspirin, which was the undisputed second place.

This year, pain after trauma was added as an indication, and Aspirin was ranked at the top. Since Aspirin’s sales surpassed ₩20 billion won in 2017, sales increased to ₩22.2 billion in 2018, but declined to ₩19.1 billion in 2019, giving Pelubi the undisputed second place.

In addition, the growth system of domestic drugs was outstanding. Boryung Biopharma's Astrix ranked fourth with ₩14.6 billion in 2019, followed by Hanmi's Naxozol with ₩10.9 billion in the same year. By pharmaceutical company, sales of companies with representative items also stood out. Pfizer Korea, which has Celebrex, is also the highest with sales of ₩40 billion in 2019.

Following this, Hanmi recorded ₩28.2 billion in the same year with increased sales of Naxozol and other NSAIDS such as Maxibupen, followed by Daewon with Pelubi at ₩26 billion.

Bayer Korea sold ₩20.4 billion to Aspirin, followed by Sinsin at ₩16.4 billion, Huons at ₩15.2 billion, and Boryung Biopharma at ₩14.9 billion.